SonoPIN: Ultrasound‑Guided Microbubbles Deliver Large Cancer Drugs with Pinpoint Precision

/in , /by

Researchers at Duke University have developed a new ultrasound‑based method called SonoPIN (“Sonoporation‑assisted Precise Intracellular Nanodelivery”) that helps large anticancer molecules get inside tumor cells with high precision, while causing minimal damage to healthy tissue. In early lab experiments, the technique killed about half of the targeted cancer cells, while more than 99% of non‑targeted […]

Read more

Enolen Implant Cuts Localized Prostate Tumor Volume by 84% in Early Study

/in , , /by

Enolen is an investigational anti‑androgen implant designed to deliver enzalutamide directly inside the prostate, aiming to shrink localized prostate tumors while minimizing systemic exposure to the drug. In data from a National Cancer Institute–led phase‑1 study, the device produced an 84% reduction in measurable tumor volume on MRI over roughly five weeks in men scheduled […]

Read more

A New CAR‑T Strategy for Bone Cancer That May Help Metastatic Prostate Disease

/in , /by

Scientists have developed a promising new CAR‑T cell therapy for osteosarcoma, the most common bone cancer in children, adolescents, and young adults, and the work carries a cautiously optimistic signal for other solid tumors, including metastatic prostate cancer. In a preclinical study, researchers at Case Western Reserve University and University Hospitals engineered T cells to […]

Read more

Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide

/in /by

A recent study, published on Nature, in metastatic castration‑resistant prostate cancer (mCRPC) shows that a simple blood test can reveal important information about how the tumor is reprogramming its metabolism and how it responds to enzalutamide, a common androgen‑receptor‑targeting drug. Researchers analyzed the entire circulating “lipidome” (the full panel of fats and related molecules in […]

Read more

Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing

/in /by

A new preclinical study shows how a simple tissue sample can be turned into a powerful tool for understanding and treating advanced prostate cancer. Researchers have developed a method to grow patient‑derived organoids from prostate tissue fragments removed during routine transurethral resection of the prostate, or TUR‑P, a common procedure often done for urinary symptoms. […]

Read more

Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial

/in , , /by

A new phase 2 EQUIP trial is comparing two different ways of delivering androgen‑suppressive hormone therapy in men with newly diagnosed or recurrent metastatic hormone‑sensitive prostate cancer, focusing on whether transdermal estrogen patches can improve quality of life compared with standard luteinizing hormone‑releasing hormone (LHRH) analogues. The study is designed around two randomized cohorts, each […]

Read more

GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer

/in , , /by

A new investigational agent code‑named GLR2037 has entered early clinical development as a first‑in‑human phase 1 study in patients with advanced prostate cancer, representing a significant step in the evolution of androgen receptor–directed therapies. GLR2037 is an androgen receptor (AR)–targeting proteolysis‑targeting chimera (PROTAC), designed not merely to inhibit the AR but to promote its ubiquitin‑proteasome–mediated […]

Read more

Durable PSA Control After Testosterone Recovery in High‑Risk Biochemical Recurrent Prostate Cancer

/in /by

A recent post hoc analysis of the phase 3 EMBARK trial in high‑risk biochemical recurrent prostate cancer has generated considerable interest because it suggests that durable, long‑term PSA control can occur even after testosterone has fully recovered to eugonadal levels, challenging the conventional assumption that hormonal suppression must be continuous to maintain remission. The analysis […]

Read more